Holen Sie sich die Stockscreener-App
45.28
1.69%
-0.78
Schlusskurs vom Vortag:
$46.06
Offen:
$45.98
24-Stunden-Volumen:
974.68K
Relative Volume:
0.71
Marktkapitalisierung:
$9.98B
Einnahmen:
$1.98B
Nettoeinkommen (Verlust:
$83.59M
KGV:
121.07
EPS:
0.374
Netto-Cashflow:
$502.31M
1W Leistung:
-4.77%
1M Leistung:
-7.54%
6M Leistung:
+14.92%
1J Leistung:
-3.40%
1-Tages-Spanne:
$45.28
$45.99
1-Wochen-Bereich:
$45.28
$47.93
52-Wochen-Spanne:
$37.74
$51.88
Qiagen Nv Stock (QGEN) Company Profile
Firmenname
Qiagen Nv
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie QGEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
45.28 | 9.98B | 1.98B | 83.59M | 502.31M | 0.374 |
|
TMO
Thermo Fisher Scientific Inc
|
479.46 | 179.95B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
190.05 | 137.90B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
641.14 | 51.04B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
123.24 | 35.19B | 6.79B | 1.22B | 1.09B | 4.26 |
|
IQV
Iqvia Holdings Inc
|
187.22 | 31.26B | 15.70B | 1.24B | 2.01B | 6.91 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-24 | Eingeleitet | Barclays | Overweight |
| 2025-04-04 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2025-02-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | Hochstufung | Jefferies | Hold → Buy |
| 2024-10-17 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-06-27 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-07 | Hochstufung | Goldman | Neutral → Buy |
| 2023-09-12 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-01-18 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-10-14 | Eingeleitet | Redburn | Buy |
| 2021-07-14 | Herabstufung | Kepler | Buy → Hold |
| 2021-06-03 | Eingeleitet | Goldman | Neutral |
| 2020-10-06 | Fortgesetzt | BofA Securities | Buy |
| 2020-09-28 | Hochstufung | Kepler | Hold → Buy |
| 2020-08-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-17 | Hochstufung | Berenberg | Hold → Buy |
| 2020-08-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-08-14 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | Herabstufung | Berenberg | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-12-26 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-11-15 | Eingeleitet | Stifel | Hold |
| 2019-11-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-11-14 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2019-11-14 | Hochstufung | Kepler | Reduce → Hold |
| 2019-10-17 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | Herabstufung | Kepler | Hold → Reduce |
| 2019-10-08 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-10-08 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Qiagen Nv Aktie (QGEN) Neueste Nachrichten
Barclays’ Significant Stake in QIAGEN Revealed by AFM - TipRanks
Cubist Systematic Strategies LLC Sells 25,043 Shares of Qiagen N.V. $QGEN - MarketBeat
Vident Advisory LLC Buys Shares of 15,040 QIAGEN N.V. $QGEN - MarketBeat
Qiagen N.V. (QGEN) Launches QIAseq xHYB Panels for Long-Read Sequencing - uk.finance.yahoo.com
Parkman Healthcare Partners LLC Raises Stake in Qiagen N.V. $QGEN - MarketBeat
Qiagen secures European CE-IVDR certification for full Qiastat-Dx portfolio - MarketScreener
QGENQIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels - mx.advfn.com
QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio - sharewise.com
Qiagen (QGEN) Earns CE-IVDR Certification for Advanced Diagnosti - GuruFocus
Transcript : Qiagen N.V. Presents at Baird Global Healthcare Conference 2025, Sep-10-2025 01 - MarketScreener
Nitorum Capital L.P. Makes New $4.42 Million Investment in Qiagen N.V. $QGEN - MarketBeat
QIAGEN Announces Voting Rights Notification by AFM - TipRanks
Edmond DE Rothschild Holding S.A. Has $19.62 Million Stake in QIAGEN N.V. $QGEN - MarketBeat
Qiagen N.V. Announces Voting Rights Notification - TipRanks
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Is Qiagen N.V. stock a smart retirement pickRecession Risk & Risk Adjusted Buy/Sell Alerts - Lancaster City Council
AI Trend Models Suggest Bounce for Qiagen N.V.2025 Trade Ideas & Long-Term Growth Portfolio Plans - beatles.ru
Ucleic Acid Amplification Testing Market Set for Dynamic - openPR.com
Perbak Capital Partners LLP Lowers Stock Position in QIAGEN N.V. $QGEN - MarketBeat
PDT Partners LLC Reduces Holdings in Qiagen N.V. $QGEN - MarketBeat
What’s next for Qiagen N.V. stockJuly 2025 Closing Moves & Technical Confirmation Trade Alerts - beatles.ru
Qiagen N.V. Announces Voting Rights Notification by AFM - The Globe and Mail
Qiagen N.V. $QGEN Shares Bought by Graham Capital Management L.P. - MarketBeat
Can swing trading help recover from Qiagen N.V. lossesWeekly Trend Recap & Accurate Technical Buy Alerts - Newser
Is Qiagen N.V. forming a bullish divergenceJuly 2025 Selloffs & Smart Allocation Stock Tips - 강소기업뉴스
What are analysts’ price targets for Qiagen N.V.July 2025 Breakouts & Accurate Buy Signal Alerts - خودرو بانک
BNP Paribas Financial Markets Decreases Stake in Qiagen N.V. $QGEN - MarketBeat
Analyzing recovery setups for Qiagen N.V. investorsBond Market & Verified High Yield Trade Plans - Newser
Qiagen N.V. stock prediction for this weekJuly 2025 Short Interest & AI Enhanced Execution Alerts - Newser
Oncology Molecular Diagnostics Market Size Drives USD 9.76 Billion by 2034 - GlobeNewswire Inc.
Is Qiagen N.V. still worth holding after the dipPortfolio Value Report & Safe Entry Momentum Tips - Newser
RNA Editing Market Top PlayersQIAGEN N.V., UniquQuire NV, LAVA - openPR.com
Raymond James Financial Inc. Sells 26,000 Shares of QIAGEN N.V. $QGEN - MarketBeat
Real time social sentiment graph for Qiagen N.V.July 2025 Pullbacks & High Yield Stock Recommendations - Newser
QIAGEN NV : Jefferies reaffirms its Buy rating - MarketScreener
What analysts say about Qiagen N.V. stock2025 Macro Impact & Free Real-Time Market Sentiment Alerts - خودرو بانک
QGEN Stock Likely to Gain From Innovation Amid Competition - MSN
Investors in Qiagen (NYSE:QGEN) have unfortunately lost 4.9% over the last five years - Yahoo Finance
Chart based analysis of Qiagen N.V. trendsWeekly Risk Summary & Daily Technical Forecast Reports - Newser
Charles Schwab Investment Management Inc. Sells 124,875 Shares of QIAGEN N.V. $QGEN - MarketBeat
Qiagen N.V. stock trend forecastChart Signals & Entry Point Confirmation Alerts - Newser
Will Qiagen N.V. outperform the market2025 Market Trends & Long Hold Capital Preservation Plans - Newser
Does Qiagen N.V. meet Warren Buffett’s criteria2025 Geopolitical Influence & Verified Short-Term Plans - خودرو بانک
Long term hold vs stop loss in Qiagen N.V.Weekly Profit Summary & Long Hold Capital Preservation Tips - Newser
Will Qiagen N.V. stock go up soonWeekly Trend Recap & Stock Portfolio Risk Control - Newser
Volatility Watch: What are analysts’ price targets for Qiagen N.V.July 2025 Weekly Recap & Verified Trade Idea Suggestions - خودرو بانک
Is Qiagen N.V. stock a good dividend stockPortfolio Profit Report & Long-Term Safe Investment Ideas - خودرو بانک
Is Qiagen N.V. stock showing strong momentumJuly 2025 Review & Low Risk High Reward Trade Ideas - خودرو بانک
Multi asset correlation models including Qiagen N.V.Earnings Beat & Technical Buy Zone Confirmation - Newser
QIAGEN Stock May Benefit From the US Clearance of QIAstat-Dx Rise - TradingView
FDA clears Qiagen’s next-gen syndrome panel - Medical Device Network
Finanzdaten der Qiagen Nv-Aktie (QGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):